Flexion Therapeutics Company Profile (NASDAQ:FLXN)

About Flexion Therapeutics (NASDAQ:FLXN)

Flexion Therapeutics logoFlexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company's other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $661.51 million
  • Outstanding Shares: 31,757,000
Average Prices:
  • 50 Day Moving Avg: $18.11
  • 200 Day Moving Avg: $20.42
  • 52 Week Range: $13.20 - $29.41
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.47
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $5.23 per share
  • Price / Book: 4.12
Profitability:
  • EBIDTA: ($75,250,000.00)
  • Return on Equity: -48.95%
  • Return on Assets: -40.44%
Debt:
  • Debt-to-Equity Ratio: 0.12%
  • Current Ratio: 10.57%
  • Quick Ratio: 10.57%
Misc:
  • Average Volume: 807,658 shs.
  • Beta: 1.16
  • Short Ratio: 6.97
 

Frequently Asked Questions for Flexion Therapeutics (NASDAQ:FLXN)

What is Flexion Therapeutics' stock symbol?

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

How were Flexion Therapeutics' earnings last quarter?

Flexion Therapeutics, Inc. (NASDAQ:FLXN) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.73) by $0.02. View Flexion Therapeutics' Earnings History.

Where is Flexion Therapeutics' stock going? Where will Flexion Therapeutics' stock price be in 2017?

8 brokers have issued twelve-month target prices for Flexion Therapeutics' shares. Their forecasts range from $0.02 to $44.00. On average, they anticipate Flexion Therapeutics' share price to reach $31.56 in the next year. View Analyst Ratings for Flexion Therapeutics.

What are analysts saying about Flexion Therapeutics stock?

Here are some recent quotes from research analysts about Flexion Therapeutics stock:

  • 1. According to Zacks Investment Research, "Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company's product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts. " (5/9/2017)
  • 2. Cantor Fitzgerald analysts commented, "OpEx Increases in 2017: FLXN reported 4Q16 and YE results of ($0.79) and ($2.84), below our estimates due to higher R&D and SG&A expense. Management noted on the call that R&D expense should increase given the on going repeat-dose study and manufacturing ramp with SG&A ramping through the 2H17 as launch preparation get fully underway. FLXN finished the quarter with $210M in cash which we estimate gives them funding through mid-2018. We have adjusted our estimates to reflect quarter results. PDUFA and Beyond: We view the acceptance of the NDA without the need to provide additional data as an incremental positive, removing an overhang in the minds of some investors. We see investors now turning to the prospective label with the potential for differentiation in the diabetic sub-population and a repeat- dose sNDA filing which could be on label by 2019. Additional label expansion into other joints including shoulder and hip are also possibilities though not near term." (3/14/2017)
  • 3. BMO Capital Markets analysts commented, "While the company did not receive a priority review, we had not been expecting that, and had always assumed a standard 10-month review. It was good to see the FDA accept the NDA with no major issues, and we remain confident in the approval of Zilretta at the PDUFA. Reiterate our Outperform; FLXN remains a top pick." (2/7/2017)

Who are some of Flexion Therapeutics' key competitors?

Who are Flexion Therapeutics' key executives?

Flexion Therapeutics' management team includes the folowing people:

  • Patrick J. Mahaffy, Chairman of the Board
  • Michael D. Clayman M.D., President, Chief Executive Officer, Co-Founder, Director
  • Neil Bodick M.D., Ph.D., Chief Scientific Officer
  • John Magee, Vice President - Sales
  • Mark Fraga, Vice President - Marketing
  • Scott Kelley M.D., Vice President - Medical Affairs
  • Dan Thornton, Vice President - Market Access
  • Yamo Deniz M.D., Chief Medical Officer
  • Mark P. Stejbach, Director
  • Scott A. Canute, Independent Director

Who owns Flexion Therapeutics stock?

Flexion Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (13.50%), Bank of New York Mellon Corp (6.69%), Vanguard Group Inc. (3.14%), TPG Group Holdings SBS Advisors Inc. (2.95%), State Street Corp (2.61%) and Peregrine Capital Management LLC (2.25%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick and Samuel D Colella. View Institutional Ownership Trends for Flexion Therapeutics.

Who sold Flexion Therapeutics stock? Who is selling Flexion Therapeutics stock?

Flexion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, Gilder Gagnon Howe & Co. LLC, Morgan Stanley, Peregrine Capital Management LLC, JPMorgan Chase & Co., Highbridge Capital Management LLC, Public Employees Retirement System of Ohio and Russell Investments Group Ltd.. Company insiders that have sold Flexion Therapeutics stock in the last year include Frederick W Driscoll and Neil Bodick. View Insider Buying and Selling for Flexion Therapeutics.

Who bought Flexion Therapeutics stock? Who is buying Flexion Therapeutics stock?

Flexion Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Pictet Asset Management Ltd., Bank of New York Mellon Corp, Ionic Capital Management LLC, EAM Investors LLC, Canada Pension Plan Investment Board, Driehaus Capital Management LLC and Mirae Asset Global Investments Co. Ltd.. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick and Samuel D Colella. View Insider Buying and Selling for Flexion Therapeutics.

How do I buy Flexion Therapeutics stock?

Shares of Flexion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Flexion Therapeutics' stock price today?

One share of Flexion Therapeutics stock can currently be purchased for approximately $21.56.


MarketBeat Community Rating for Flexion Therapeutics (NASDAQ FLXN)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Flexion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Flexion Therapeutics (NASDAQ:FLXN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.13)
Consensus Price Target: $31.56 (46.37% upside)

Analysts' Ratings History for Flexion Therapeutics (NASDAQ:FLXN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/27/2017BMO Capital MarketsReiterated RatingBuyHighView Rating Details
6/12/2017Cantor FitzgeraldSet Price TargetBuy$40.00LowView Rating Details
5/15/2017Needham & Company LLCReiterated RatingBuy$34.00HighView Rating Details
3/26/2017Royal Bank Of CanadaSet Price TargetBuy$44.00HighView Rating Details
3/25/2017Wells Fargo & CompanyReiterated RatingOutperform$30.00MediumView Rating Details
3/11/2017Janney Montgomery ScottReiterated RatingBuy$30.00N/AView Rating Details
12/22/2016Raymond James Financial, Inc.Initiated CoverageStrong-Buy$35.00N/AView Rating Details
11/8/2016BCSLower Price Target$0.65 -> $0.02N/AView Rating Details
9/6/2016Lake Street CapitalReiterated RatingBuy$38.00N/AView Rating Details
9/2/2015Northland SecuritiesReiterated RatingBuy$40.00N/AView Rating Details
(Data available from 6/29/2015 forward)

Earnings

Earnings History for Flexion Therapeutics (NASDAQ:FLXN)
Earnings by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Earnings History by Quarter for Flexion Therapeutics (NASDAQ FLXN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.73)($0.75)ViewListenView Earnings Details
3/9/2017Q4 2016($0.71)($0.79)ViewListenView Earnings Details
11/7/2016Q3($0.63)($0.65)ViewListenView Earnings Details
8/3/2016Q2($0.67)($0.63)ViewN/AView Earnings Details
5/12/2016Q1($0.61)($0.78)ViewListenView Earnings Details
3/10/2016Q4 2015($0.58)($0.63)ViewN/AView Earnings Details
11/9/2015Q3($0.60)($0.52)ViewListenView Earnings Details
8/6/2015Q215($0.54)($0.58)ViewN/AView Earnings Details
5/7/2015Q115($0.56)($0.43)ViewN/AView Earnings Details
3/23/2015Q4 2014($0.46)($0.47)ViewN/AView Earnings Details
11/13/2014Q314($0.54)($0.45)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.55)($0.38)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.53)($0.86)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Flexion Therapeutics (NASDAQ:FLXN)
Current Year EPS Consensus Estimate: $-3.35 EPS
Next Year EPS Consensus Estimate: $-2.06 EPS

Dividends

Dividend History for Flexion Therapeutics (NASDAQ:FLXN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Flexion Therapeutics (NASDAQ:FLXN)
Insider Ownership Percentage: 18.00%
Institutional Ownership Percentage: 75.35%
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Insider Trades by Quarter for Flexion Therapeutics (NASDAQ:FLXN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2017Mark StejbachDirectorBuy1,580$17.02$26,891.60View SEC Filing  
6/5/2017Michael D ClaymanInsiderBuy5,000$17.23$86,150.00View SEC Filing  
4/17/2017Neil BodickInsiderSell5,000$28.23$141,150.00View SEC Filing  
3/23/2017Frederick W DriscollCFOSell3,000$23.00$69,000.00View SEC Filing  
3/17/2017Neil BodickInsiderSell5,000$20.41$102,050.00View SEC Filing  
2/24/2017Neil BodickInsiderSell5,000$19.15$95,750.00View SEC Filing  
1/20/2017Neil BodickInsiderSell5,000$18.35$91,750.00View SEC Filing  
12/21/2016Neil BodickInsiderSell10,000$18.46$184,600.00View SEC Filing  
12/1/2016Samuel D ColellaDirectorBuy10,000$16.38$163,800.00View SEC Filing  
11/23/2016Michael D ClaymanInsiderBuy1,667$18.41$30,689.47View SEC Filing  
11/22/2016Michael D ClaymanInsiderBuy1,666$17.95$29,904.70View SEC Filing  
11/21/2016Michael D ClaymanInsiderBuy1,666$17.90$29,821.40View SEC Filing  
11/21/2016Samuel D ColellaDirectorBuy33,333$18.00$599,994.00View SEC Filing  
6/21/2016Samuel D ColellaDirectorBuy25,504$13.71$349,659.84View SEC Filing  
6/20/2016Samuel D ColellaDirectorBuy6,778$13.84$93,807.52View SEC Filing  
6/14/2016C Ann MerrifieldDirectorBuy1,000$13.39$13,390.00View SEC Filing  
6/8/2016Samuel D ColellaDirectorBuy714,285$14.00$9,999,990.00View SEC Filing  
5/20/2016Michael D ClaymanCEOBuy2,000$10.41$20,820.00View SEC Filing  
5/19/2016Michael D ClaymanCEOBuy2,000$9.65$19,300.00View SEC Filing  
5/19/2016Neil BodickInsiderBuy850$10.00$8,500.00View SEC Filing  
5/18/2016Michael D ClaymanCEOBuy2,000$10.23$20,460.00View SEC Filing  
5/18/2016Neil BodickInsiderBuy2,100$10.20$21,420.00View SEC Filing  
5/17/2016Frederick W DriscollCFOBuy2,500$9.87$24,675.00View SEC Filing  
5/17/2016Michael D ClaymanCEOBuy2,000$9.73$19,460.00View SEC Filing  
5/17/2016Neil BodickInsiderBuy800$9.60$7,680.00View SEC Filing  
5/16/2016Frederick W DriscollCFOBuy2,500$9.19$22,975.00View SEC Filing  
5/16/2016Michael D ClaymanCEOBuy2,000$9.51$19,020.00View SEC Filing  
5/16/2016Neil BodickInsiderBuy1,250$9.22$11,525.00View SEC Filing  
9/11/2015C Ann MerrifieldDirectorBuy1,000$23.00$23,000.00View SEC Filing  
6/22/2015A/S NovoMajor ShareholderSell150,000$20.61$3,091,500.00View SEC Filing  
3/16/2015Neil BodickInsiderSell4,000$25.28$101,120.00View SEC Filing  
3/10/2015Neil BodickInsiderSell4,000$24.26$97,040.00View SEC Filing  
3/4/2015Neil BodickInsiderSell4,000$23.45$93,800.00View SEC Filing  
2/26/2015Neil BodickInsiderSell4,000$22.44$89,760.00View SEC Filing  
12/17/2014A/S NovoMajor ShareholderBuy500,000$17.00$8,500,000.00View SEC Filing  
2/18/2014A/S NovoInsiderBuy692,308$13.00$9,000,004.00View SEC Filing  
2/18/2014Bradley J Phd BolzonDirectorBuy307,692$13.00$3,999,996.00View SEC Filing  
2/18/2014Sofinnova Partners SasMajor ShareholderBuy230,769$13.00$2,999,997.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Flexion Therapeutics (NASDAQ:FLXN)
Latest Headlines for Flexion Therapeutics (NASDAQ:FLXN)
Source:
DateHeadline
seekingalpha.com logoThe Investment Case For Flexion Therapeutics - Seeking Alpha
seekingalpha.com - June 29 at 4:23 AM
finance.yahoo.com logoFlexion Therapeutics Announces Appointment of Mark Levine as General Counsel
finance.yahoo.com - June 28 at 6:17 PM
americanbankingnews.com logoBMO Capital Markets Reiterates Buy Rating for Flexion Therapeutics, Inc. (FLXN)
www.americanbankingnews.com - June 27 at 9:52 AM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 26 at 8:42 PM
americanbankingnews.com logo Brokerages Expect Flexion Therapeutics, Inc. (FLXN) Will Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - June 26 at 12:30 PM
finance.yahoo.com logoFlexion Therapeutics Named One of Boston Business Journal’s Best Places to Work
finance.yahoo.com - June 23 at 5:52 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - June 21 at 10:38 PM
americanbankingnews.com logoMark Stejbach Purchases 1,580 Shares of Flexion Therapeutics, Inc. (FLXN) Stock
www.americanbankingnews.com - June 20 at 8:42 PM
americanbankingnews.com logoFlexion Therapeutics, Inc. (FLXN) Given a $40.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - June 13 at 2:12 PM
seekingalpha.com logo2 Small Biotechs That Could Soar In Second Half Of 2017 - Seeking Alpha
seekingalpha.com - June 11 at 3:19 AM
globenewswire.com logoFlexion Therapeutics to Present Data on Zilretta™ (FX006) at the American Diabetes Association's 77th Scientific ... - GlobeNewswire (press release)
globenewswire.com - June 10 at 5:19 PM
finance.yahoo.com logoFlexion Therapeutics to Present Data on Zilretta™ (FX006) at the American Diabetes Association’s 77th Scientific Sessions
finance.yahoo.com - June 10 at 5:19 PM
americanbankingnews.com logoMichael D. Clayman Purchases 5,000 Shares of Flexion Therapeutics Inc (FLXN) Stock
www.americanbankingnews.com - June 6 at 8:42 PM
americanbankingnews.com logo Brokerages Expect Flexion Therapeutics Inc (FLXN) Will Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - May 31 at 8:10 AM
americanbankingnews.com logoFlexion Therapeutics Inc (FLXN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 30 at 6:34 PM
americanbankingnews.com logoFlexion Therapeutics Inc (FLXN) Short Interest Update
www.americanbankingnews.com - May 26 at 7:17 AM
streetinsider.com logoFlexion Therapeutics (FLXN) to Announce New Cost-Effectiveness Data on Zilretta™ (FX006) at ISPOR Meetings on ... - StreetInsider.com
www.streetinsider.com - May 24 at 12:07 PM
americanbankingnews.com logoFlexion Therapeutics Inc (FLXN) Given a $40.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 23 at 8:04 PM
finance.yahoo.com logoFlexion CEO on developing an alternative to opioids
finance.yahoo.com - May 23 at 4:55 PM
streetinsider.com logoFlexion Therapeutics (FLXN) Announces Upcoming Data Presentation at ADA's Scientific Sessions - StreetInsider.com
www.streetinsider.com - May 19 at 6:58 AM
streetinsider.com logoFlexion Therapeutics (FLXN) Announces Upcoming Data Presentation at ADA's Scientific Sessions
www.streetinsider.com - May 18 at 10:08 AM
finance.yahoo.com logoFlexion Therapeutics Announces Upcoming Data Presentation at the American Diabetes Association's 77th Scientific Sessions
finance.yahoo.com - May 18 at 10:08 AM
americanbankingnews.com logoNeedham & Company LLC Reaffirms Buy Rating for Flexion Therapeutics Inc (FLXN)
www.americanbankingnews.com - May 15 at 12:42 PM
americanbankingnews.com logoFY2017 Earnings Estimate for Flexion Therapeutics Inc (FLXN) Issued By Cantor Fitzgerald
www.americanbankingnews.com - May 12 at 12:52 PM
finance.yahoo.com logoAnother top executive at ​Sanofi Genzyme leaves company
finance.yahoo.com - May 10 at 10:25 PM
americanbankingnews.com logoFlexion Therapeutics Inc (FLXN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:30 PM
seekingalpha.com logoFlexion Therapeutics' (FLXN) CEO Mike Clayman on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 5 at 5:24 PM
finance.yahoo.com logoEdited Transcript of FLXN earnings conference call or presentation 4-May-17 8:30pm GMT
finance.yahoo.com - May 5 at 5:24 PM
americanbankingnews.com logoFlexion Therapeutics Inc (FLXN) Issues Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - May 5 at 4:40 PM
americanbankingnews.com logoFlexion Therapeutics Inc (FLXN) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 5 at 12:55 PM
americanbankingnews.com logo Analysts Expect Flexion Therapeutics Inc (FLXN) Will Post Earnings of -$0.76 Per Share
www.americanbankingnews.com - May 5 at 11:18 AM
marketbeat.com logoFlexion Therapeutics reports 1Q loss
marketbeat.com - May 4 at 6:57 PM
finance.yahoo.com logoFlexion Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights
finance.yahoo.com - May 4 at 5:22 PM
finance.yahoo.com logoInvestor Network: Flexion Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - May 4 at 12:23 PM
nasdaq.com logoFlexion Therapeutics to Present at the Deutsche Bank 42nd Annual ... - Nasdaq
www.nasdaq.com - May 1 at 5:02 PM
finance.yahoo.com logoFlexion Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - May 1 at 9:53 AM
finance.yahoo.com logoFlexion Therapeutics Highlights Two Clinical Data Presentations at the Osteoarthritis Research Society International ... - Yahoo Finance
finance.yahoo.com - April 29 at 5:52 PM
americanbankingnews.com logoFlexion Therapeutics (FLXN) Getting Somewhat Positive News Coverage, Analysis Shows
www.americanbankingnews.com - April 28 at 4:04 PM
globenewswire.com logoFlexion Therapeutics Highlights Two Clinical Data Presentations at the Osteoarthritis Research Society International ... - GlobeNewswire (press release)
globenewswire.com - April 28 at 8:56 AM
finance.yahoo.com logoFlexion Therapeutics Highlights Two Clinical Data Presentations at the Osteoarthritis Research Society International 2017 World Congress
finance.yahoo.com - April 28 at 8:56 AM
streetinsider.com logoFlexion Therapeutics (FLXN) Announces Proposed Convertible Senior Notes Offering
www.streetinsider.com - April 26 at 8:11 PM
finance.yahoo.com logoFlexion Therapeutics Announces Pricing of $175 Million 3.375% Convertible Senior Notes due 2024
finance.yahoo.com - April 26 at 8:11 PM
americanbankingnews.com logoFlexion Therapeutics' (FLXN) Buy Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - April 26 at 2:42 PM
fool.com logoWhy Flexion Therapeutics Inc. Stock Is Tanking
www.fool.com - April 26 at 1:01 PM
finance.yahoo.com logoFlexion Therapeutics Announces Proposed Convertible Senior Notes Offering
finance.yahoo.com - April 25 at 4:52 PM
americanbankingnews.com logoFlexion Therapeutics (FLXN) Getting Somewhat Critical News Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 1:08 PM
finance.yahoo.com logoFlexion Therapeutics to Report First-Quarter 2017 Financial Results on May 4, 2017
finance.yahoo.com - April 25 at 11:22 AM
americanbankingnews.com logoFlexion Therapeutics (FLXN) Earns Daily News Sentiment Score of 0.07
www.americanbankingnews.com - April 21 at 8:21 PM
finance.yahoo.com logoWhy Flexion Therapeutics' New Pain Drug Could Be a Game-Changer
finance.yahoo.com - April 19 at 5:09 PM
americanbankingnews.com logoNeil Bodick Sells 5,000 Shares of Flexion Therapeutics Inc (FLXN) Stock
www.americanbankingnews.com - April 18 at 10:59 PM

Social

Chart

Flexion Therapeutics (FLXN) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by MarketBeat.com Staff